|
Painful HIV Neuropathy and Alpha-Lipoic Acid Clinical Trials Data presented on Clinical Trials Search is not meant to be a substitute for qualified medical advice, visits or professional assistance with a genuine dr.. We are not doctors. Always consult your mD about Painful HIV Neuropathy and Alpha-Lipoic Acid conditions. Clinical Trials Search.org is a site devoted to listing clinical research studies in human subjects. Painful HIV Neuropathy and Alpha-Lipoic Acid Clinical research trials and Painful HIV Neuropathy and Alpha-Lipoic Acid medical trials take place in many of places throughout the U.S.A.. A clinical trial or clinical study is a research project with human volunteer subjects. Clinical drug trials and pharmaceutical clinical trials usually evaluate the effectiveness of new does drugs. The purpose of the studies / projects is to solve specific human healthcare questions. Clinical trials are a popular way for mDs, government agencies, and private sector companies to find cures for all varieties of conditions, like Painful HIV Neuropathy and Alpha-Lipoic Acid. Painful HIV Neuropathy and Alpha-Lipoic Acid Clinical Trials and other clinical trials allow for volunteers to have health treatment options before they are available to the masses. Many times the human subjects acquire professional assistance for free of charge, and sometimes they are compensated for their time. Occasionally there is a cost for a Painful HIV Neuropathy and Alpha-Lipoic Acid clinical trial. Test subjects typically obtain the finest healthcare available for their Painful HIV Neuropathy and Alpha-Lipoic Acid condition. Dangers are a reality, nevertheless, and might include additional or frequent doctor trips, medical dangers (possibly life-jeopardising), and/or the treatment being ineffectual. Trials are federally regulated with strict guidelines to protect clinical trials patients.
|
|
|
|
|
|
|
Home > "P" Clinical Trials Conditions > Painful HIV Neuropathy and Alpha-Lipoic Acid  Painful HIV Neuropathy and Alpha-Lipoic Acid
Painful HIV Neuropathy and Alpha-Lipoic Acid
For Condition: Peripheral Neuropathy,HIV
Status: Not yet recruiting
Sponsor(s): National Center for Complementary and Alternative Medicine (NCCAM) ,
Synopsis: HIV is associated with painful peripheral neuropathy. Disability is often significant. Alpha-Lipoic Acid's antioxidant properties may have benefit in this condition.
Details: HIV is associated with painful distal peripheral polyneuropathy in up to 35-50% of those without AIDS and in more than 70% of those with advanced disease. The condition is progressive but may be halted with disease remission. Disability is often significant. Peripheral nerve axons and sensory neuron cell bodies in the dorsal root ganglia are the principal targets of the process leading to symptoms. Alpha-lipoic acid occurs naturally in every cell of the body. In high concentrations it acts as an anti-oxidant which regenerates other anti-oxidants and promotes glutathione synthesis. Clinical studies for diabetic neuropathy have shown significant benefit at daily oral doses that are well-tolerated. This placebo-controlled study is designed to evaluate the effects of daily oral alpha-lipoic acid supplements (600mg, three times per/day) plus standard medical care in the treatment of painful HIV-associated neuropathy over a 24-week period in adult subjects. Possible benefits of the study include reduction in pain and disability, reduced use of medications, and enhanced cellular metabolism.
Eligibility:
Study Type: Interventional, Treatment, Randomized, Double-Blind, Placebo Control, Parallel Assignment, Efficacy Study
Minimum Age/Maximum Age: 18 Years/
Genders: Both
Protocol Entry Criteria: Inclusion Criteria: - HIV-seropositive - Distal peripheral sensory neuropathy as diagnosed by a neurologist with pain or paresthesia, with or without numbness or weakness - Able to understand and participate in protocol activities - Able to give informed consent - Under the care of a UNC ID Clinical physician for at least 2 months - Able to document pain characteristics, use of pain medications, and other assessment instruments and characteristics - On stable antiretroviral therapy (or none) for 12 weeks prior to enrollment - No changes in peripheral neuropathy pharmacologic treatment for 12 weeks prior to enrollment Exclusion Criteria: - Any significant cognitive impairment or psychosis - Pregnancy or anticipated pregnancy (women of child-bearing potential must agree to use birth control for the duration of the study) - Undergoing any current treatment for malignancy, including chemotherapy or radiation therapy within the past year - Concurrent or prior use of a-LA - Known non-HIV risk factors for peripheral neuropathy, such as DM, B12/folate deficiency; thyroid dysfunction; hx of exposure to lead, mercury, arsenic, thallium (prior diagnostic tests permitted), other heavy metals or complex hydrocarbons - Use of metronidazole, isoniazid or other furantoins - Suspected or documented thiamin deficiency - Active alcoholism - Allergy to a-LA - Hx of ‘significant’ use of anti-oxidant supplements during the two months prior to study entry
Total Enrollment: 60
Location and Contact Information:
University of North Carolina Chapel Hill
Chapel Hill, North Carolina, 27599-7025
United States
John Mann 919-966-8975
Additional Information:
Study ID Numbers: R21AT1775; MannJ
Study Start Date: September 2003
Record last reviewed: April 2004
Additional information available at: clinicaltrials.gov
Clinicaltrials.gov Reference link: NCT00079807
Other Peripheral Neuropathy Studies:
1. Painful HIV Neuropathy and Alpha-Lipoic Acid
2. Achilles Tendon Lengthening in Patients with Diabetes to Prevent Foot Ulcers
3. A study of Rituxan in the treatment of polyneuropathies associated with serum IgM autoantibodies
Related Studies:
Other Peripheral Neuropathy Clinical Trials
Other North Carolina Clinical Trials
Other Chapel Hill Clinical Trials
Painful HIV Neuropathy and Alpha-Lipoic Acid
|
|
|
|
|
|
|
|
